Macrocyclic peptidomimetic beta-secretase (BACE-1) inhibitors with activity in vivo.

[1]  Jean-Michel Rondeau,et al.  Structure-based design and synthesis of macrocyclic peptidomimetic beta-secretase (BACE-1) inhibitors. , 2009, Bioorganic & medicinal chemistry letters.

[2]  M. Stoeckli,et al.  Dynamics of Aβ Turnover and Deposition in Different β-Amyloid Precursor Protein Transgenic Mouse Models Following γ-Secretase Inhibition , 2008, Journal of Pharmacology and Experimental Therapeutics.

[3]  P. Reinemer,et al.  Macrocyclic Statine‐Based Inhibitors of BACE‐1 , 2007, Chembiochem : a European journal of chemical biology.

[4]  A. Simon,et al.  Strategies toward improving the brain penetration of macrocyclic tertiary carbinamine BACE-1 inhibitors. , 2007, Bioorganic & medicinal chemistry letters.

[5]  L. Vecchia,et al.  Optimized Synthesis of l-m-Tyrosine Suitable for Chemical Scale-Up , 2007 .

[6]  D. Hazuda,et al.  Design, synthesis, and SAR of macrocyclic tertiary carbinamine BACE-1 inhibitors. , 2007, Bioorganic & medicinal chemistry letters.

[7]  M. Katharine Holloway,et al.  Macrocyclic Inhibitors of β-Secretase: Functional Activity in an Animal Model. , 2006 .

[8]  V. Laurent-Matha,et al.  Cathepsin D: newly discovered functions of a long-standing aspartic protease in cancer and apoptosis. , 2006, Cancer letters.

[9]  O. Ghisalba,et al.  Easy Access to Enantiomerically Pure Nonproteinogenic Amino Acids , 2006 .

[10]  Stephen Hanessian,et al.  Structure-based design, synthesis, and memapsin 2 (BACE) inhibitory activity of carbocyclic and heterocyclic peptidomimetics. , 2005, Journal of medicinal chemistry.

[11]  I. Hidalgo,et al.  Evaluation of the MDR-MDCK cell line as a permeability screen for the blood-brain barrier. , 2005, International journal of pharmaceutics.

[12]  Lin Hong,et al.  Structure-based design of cycloamide–urethane-derived novel inhibitors of human brain memapsin 2 (β-secretase) , 2005 .

[13]  C. Haass.  Take five—BACE and the γ‐secretase quartet conduct Alzheimer's amyloid β‐peptide generation , 2004 .

[14]  W. Richards,et al.  Mice deficient in BACE1, the Alzheimer's β-secretase, have normal phenotype and abolished β-amyloid generation , 2001, Nature Neuroscience.

[15]  O. Ghisalba,et al.  Enzyme-assisted Preparation of D-tert.-Leucine , 2001, Bioscience, biotechnology, and biochemistry.

[16]  R. Barbour,et al.  Purification and cloning of amyloid precursor protein β-secretase from human brain , 1999, Nature.

[17]  Alfredo G. Tomasselli,et al.  Membrane-anchored aspartyl protease with Alzheimer's disease β-secretase activity , 1999, Nature.

[18]  David G. Tew,et al.  Identification of a Novel Aspartic Protease (Asp 2) as β-Secretase , 1999, Molecular and Cellular Neuroscience.

[19]  J. Treanor,et al.  Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. , 1999, Science.

[20]  R. Grubbs,et al.  Increased ring closing metathesis activity of ruthenium-based olefin metathesis catalysts coordinated with imidazolin-2-ylidene ligands , 1999 .

[21]  G. Glenner,et al.  Alzheimer's disease: Initial report of the purification and characterization of a novel cerebrovascular amyloid protein , 1984 .

[22]  A. Barrett.  Cathepsin D. Purification of isoenzymes from human and chicken liver. , 1970, The Biochemical journal.

[23]  A. Alzheimer.  über eigenartige Krankheitsfälle des späteren Alters , 1911 .

[24]  J. Hardy,et al.  The Amyloid Hypothesis of Alzheimer ’ s Disease : Progress and Problems on the Road to Therapeutics , 2009 .

[25]  D. Timm,et al.  Macrocyclic peptidomimetic inhibitors of beta-secretase (BACE): first X-ray structure of a macrocyclic peptidomimetic-BACE complex. , 2006, Bioorganic & medicinal chemistry letters.